Ionis Pharmaceuticals Inc.
IONS Nasdaq
SEC CIK 874015
Follow Ionis Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$242.7M
+54.9% vs same quarter last year
Net income
−$110M
+14.5% vs same quarter last year
EPS, diluted
−$0.66
+17.5% vs same quarter last year
Operating cash flow
−$179.4M
−36.5% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $943.7M | −$381.4M |
| FY24 | $705.1M | −$453.9M |
| FY23 | $787.6M | −$366.3M |
| FY22 | $587.4M | −$269.7M |
| FY21 | $810.5M | −$28.6M |
| FY20 | $729.3M | −$444.3M |
| FY19 | $1.1B | $278.1M |
| FY18 | $599.7M | $273.7M |
| FY17 | $514.2M | $346K |
| FY16 | $372.8M | −$60.4M |
| FY15 | $283.7M | −$88.3M |
| FY14 | $214.2M | −$39M |
| FY13 | $147.3M | −$60.6M |
| FY12 | $102M | −$65.5M |
| FY11 | $99.1M | −$84.8M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 98.3% | −40.4% | −40.4% |
| FY24 | 98.4% | −67.4% | −64.4% |
| FY23 | 98.8% | −44.9% | −46.5% |
| FY22 | 97.6% | −69.8% | −45.9% |
| FY21 | 98.7% | −3.7% | −3.5% |
| FY20 | 98.4% | −23.6% | −60.9% |
| FY19 | 99.6% | 32.6% | 24.8% |
| FY18 | 99.7% | −10.2% | 45.6% |
| FY17 | 100% | 6% | 0.1% |
| FY16 | 100% | −5.4% | −16.2% |
| FY15 | - | −26.7% | −31.1% |
| FY14 | - | −22.3% | −18.2% |
| FY13 | - | −35.1% | −41.2% |
| FY12 | - | −67.5% | −64.2% |
| FY11 | - | −71.8% | −85.6% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$320M |
| FY24 | −$546.2M |
| FY23 | −$331.3M |
| FY22 | −$290.1M |
| FY21 | $18.8M |
| FY20 | $772K |
| FY19 | $314.7M |
| FY18 | $589.3M |
| FY17 | $139.4M |
| FY16 | −$119.2M |
| FY15 | $13.4M |
| FY14 | −$1.2M |
| FY13 | $61.9M |
| FY12 | $397K |
| FY11 | −$125M |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | $0 |
| FY21 | $0 |
| FY20 | $90.5M |
| FY19 | $34.4M |
| FY18 | $0 |
| FY17 | $0 |
| FY16 | - |
| FY15 | - |
| FY14 | - |
| FY13 | - |
| FY12 | - |
| FY11 | - |
- Ionis Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Ionis Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | −40.4% | −30.6% |
| FY24 | −64.4% | −47% |
| FY23 | −46.5% | −58% |
| FY22 | −45.9% | −80.4% |
| FY21 | −3.5% | −71.9% |
| FY20 | −60.9% | −62.2% |
| FY19 | 24.8% | −46.3% |
| FY18 | 45.6% | −49.6% |
| FY17 | 0.1% | −45.9% |
| FY16 | −16.2% | −36% |
| FY15 | −31.1% | −38.4% |
| FY14 | −18.2% | −35.5% |
| FY13 | −41.2% | −37.1% |
| FY12 | −64.2% | −29.1% |
| FY11 | −85.6% | −27.9% |